fda semaglutide shortage resolved 2025 announcement Ozempic and Wegovy are no longer in shortage, says FDA resolves tirzepatide shortage, impacting

Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists

Getting B12 vitamin shots can indirectly help you make these positive lifestyle changes

Malaguarnera et al., 2006)

It is important to distinguish between a simple medication depot and more serious complications such as lipohypertrophy (fatty lumps from repeated injections in the same site) or injection site abscesses